Advertisement

International Journal of Hematology

, Volume 110, Issue 2, pp 205–212 | Cite as

Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia

  • Anudishi Tyagi
  • Raja Pramanik
  • Radhika Bakhshi
  • Archna Singh
  • Sreenivas Vishnubhatla
  • Sameer BakhshiEmail author
Original Article
  • 61 Downloads

Abstract

Deregulated mitochondrial metabolism and biogenesis have been studied in acute myeloid leukemia (AML); yet, the relevance of mitochondrial-encoded gene expression on AML outcomes is unknown. This study was conducted to assess clinical significance of expression of mitochondrial-encoded genes, namely ND3, SDHB, Cytochrome b, Cytochrome C, and ATP6, in pediatric AML. Pediatric AML patients from July 2013 to June 2016 were enrolled in this prospective study. Relative genes expression was determined using real-time PCR, and expressed as fold change. 123 AML patients were enrolled, median age 10 (range 0.7–18 years). ND3 gene expression was significantly increased in poor-risk cytogenetics (P = 0.03). In univariate analysis, high ND3 and ATP6 gene expression was significantly associated with inferior EFS (P = 0.01 and P = 0.04, respectively) and OS (P = 0.02 and P = 0.01, respectively), whereas, in multivariate analysis, ND3 gene expression emerged as the only independent prognostic factor for EFS and OS (P = 0.04 and P = 0.03). ND3 gene expression is a significant predictor of EFS and OS in pediatric AML, and should be evaluated as a potential biomarker.

Keywords

Mitochondrial Gene expression ND3 Pediatric Acute myeloid leukemia 

Notes

Acknowledgements

We thank our nursing staff, data entry operator, patients and their parents who participated in the study. We also acknowledge the following funding agency 1. AIIMS, (Grant no. F.5-59/IRG/2010/RS) Intramural Grant.

Author contributions

AT and SB designed the study; AT, RB, and AS contribute to acquisition and interpretation of data; SV was the statistician, analyzed and interpreted the results; AT, RP, and SB wrote the paper. All authors reviewed and gave the final approval for the paper.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Approval for the study was taken from the Institute Ethical Committee vide letter number: IEC/NP-336/2012.

References

  1. 1.
    Wallace DC. Diseases of the mitochondrial DNA. Annu Rev Chem Biomol Eng. 1992;61:1175–212.Google Scholar
  2. 2.
    Grossman L. Mitochondrial DNA mutations and human disease. Environ Mutagen. 1995;25:30–7.CrossRefGoogle Scholar
  3. 3.
    Larsson NG, Luft R. Revolution in mitochondrial medicine. FEBS Lett. 1999;455:199–202.CrossRefGoogle Scholar
  4. 4.
    Grossman L, Shoubridge E. Mitochondrial genetics and human disease. BioEssays. 1996;18:983–91.CrossRefGoogle Scholar
  5. 5.
    Weiss H, Friedrich T, Hofhaus G, Preis D. The respiratory-chain NADH dehydrogenase (complex 1) of mitochondria. Eur J Biochem. 1991;197:563–76.CrossRefGoogle Scholar
  6. 6.
    Hatefi Y. The mitochondrial phosphorylation system and oxidative phosphorylation. Annu Rev Biochem. 1985;54:1015–69.CrossRefGoogle Scholar
  7. 7.
    Robinson BH. Human complex I deficiency: clinical spectrum and involvement of oxygen free radicals in the pathogenicity of the defect. Biochim Biophys Acta. 1998;1364:271–86.CrossRefGoogle Scholar
  8. 8.
    Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer. 2002;1:1–12.CrossRefGoogle Scholar
  9. 9.
    Fliss MS, Usadel H, Cobarello OL. Facile detection of mitochondrial DNA mutations in tumours and bodily fluids. Science. 2000;287:2017–9.CrossRefGoogle Scholar
  10. 10.
    Bianchi MS, Bianchi NO, Bailliet G. Mitochondrial DNA mutations in normal and tumor tissues from breast cancer patients. Cytogenet Cell Genet. 1995;71:99–103.CrossRefGoogle Scholar
  11. 11.
    Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet. 1998;20:291–3.CrossRefGoogle Scholar
  12. 12.
    Horton TM, Petros JA, Heddi A, Shoffner J, Kaufman AE, Graham SD Jr, et al. Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer. 1996;15:95–101.CrossRefGoogle Scholar
  13. 13.
    Luciakovak KS. Increased steady-state levels of several mitochondrial and nuclear gene transcripts in rat hepatoma with a low content of mitochondria. Eur J Biochem. 1992;205:1187–93.CrossRefGoogle Scholar
  14. 14.
    Tamura G, Nishizuka S, Maesawa C, Suzuki Y, Lwaya T, Sakata K, et al. Mutations in mitochondrial control region DNA in gastric tumours of Japanese patients. Eur J Cancer. 1999;35:316–9.CrossRefGoogle Scholar
  15. 15.
    Clayton DA, Vinograd J. Circular dimer and catenate forms of mitochondrial DNA in human leukaemic leucocytes. Nature. 1967;216:652–7.CrossRefGoogle Scholar
  16. 16.
    LaBiche RA, Yoshida M, Gallick GE, Irimura T, Robberson DL, Klostergaard J, et al. Gene expression and tumor cell escape from host effector mechanisms in murine large cell lymphoma. J Cell Biochem. 1988;36:393–403.CrossRefGoogle Scholar
  17. 17.
    Sharp MGF, Adams SM, Walker RA, Brammar WJ, Varley JM. Differential expression of the mitochondrial gene cytochrome oxidase II in benign and malignant breast tissue. J Pathol. 1992;168:163–8.CrossRefGoogle Scholar
  18. 18.
    Lu X, Walker T, Macmanus JP, Walker T, Macmanus JP, Seligy VL. Differentiation of HT-29 human colonic adenocarcinoma cells correlates with increased expression of mitochondrial RNA: effects of trehalose on cell growth and maturation differentiation of HT-29 human colonie adenocarcinoma cells correlates with increase. Cancer Res. 1992;37:18–25.Google Scholar
  19. 19.
    Reznik E, Miller ML, Şenbabaoğlu Y, Riaz N, Sarungbam J, Tickoo SK, et al. Mitochondrial DNA copy number variation across human cancers. ELife. 2016;5:1–20.CrossRefGoogle Scholar
  20. 20.
    Reznik ED, Wang Q, La K, Schultz N, Sander C. Mitochondrial respiratory gene expression is suppressed in many cancers. ELife. 2017;6:1–16.CrossRefGoogle Scholar
  21. 21.
    Schildgen V, Wulfert M, Gattermann N. Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes. Exp Hematol. 2011;39:666–75.CrossRefGoogle Scholar
  22. 22.
    Tyagi A, Pramanik R, Vishnubhatla S, Ali S, Bakhshi R, Chopra A, et al. Pattern of mitochondrial D-loop variations and their relation with mitochondrial encoded genes in pediatric acute myeloid leukemia. Mutat Res. 2018;810:13–8.CrossRefGoogle Scholar
  23. 23.
    Shaffer LG, McGowan-Jordan J, Schmid M. An international system for human cytogenetic nomenclature (ISCN). Basel: Karger; 2013. p. 88–95.Google Scholar
  24. 24.
    Chopra A, Soni S, Pati H, Kumar D, Diwedi R, Verma D, et al. Nucleophosmin mutation analysis in acute myeloid leukaemia: immunohistochemistry as a surrogate for molecular techniques. Indian J Med Res. 2016;143:763–8.CrossRefGoogle Scholar
  25. 25.
    Sharawat SK, Raina V, Kumar L, Sharma A, Bakhshi R, Vishnubhatla S, et al. High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in FLT3 internal tandem duplication (ITD) negative patients in adult acute myeloid leukaemia: a prospective pilot study from India. Indian J Med Res. 2016;143:S11–S16.Google Scholar
  26. 26.
    Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from international panel. Blood. 2017;129:424–48.CrossRefGoogle Scholar
  27. 27.
    Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2016;125:3878–86.CrossRefGoogle Scholar
  28. 28.
    Ahmad F, Mandava S, Das BR. Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population. Cancer Investig. 2010;28:63–73.CrossRefGoogle Scholar
  29. 29.
    Wulfert M, Küpper AC, Tapprich C, Bottomley SS, Bowen D, Germing U, et al. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol. 2008;36:577–86.CrossRefGoogle Scholar
  30. 30.
    Chen ML, Logan TD, Hochberg ML, Shelat SG, Yu X, Wilding GE, et al. Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction. Blood. 2009;114:4045–53.CrossRefGoogle Scholar
  31. 31.
    Sotgia F, Lisanti MP. Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: use as companion diagnostics. Oncotarget. 2017;8:68095–107.Google Scholar
  32. 32.
    Sotgia F, Fiorillo M, Lisanti MP. Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: early detection of treatment failure with companion diagnostics. Oncotarget. 2017;8:68730–45.Google Scholar
  33. 33.
    Selvanayagam P, Rajaraman S. Detection of mitochondrial genome depletion by a novel cDNA in renal cell carcinoma. Lab Investig. 1996;74:592.Google Scholar
  34. 34.
    Wong TWL, Yu HY, Kong SK, Fung KP, Kwok TT. The decrease of mitochondrial NADH dehydrogenase and drug induced apoptosis in doxorubicin resistant A431 cells. Life Sci. 2000;67:1111–8.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Department of Medical OncologyDr. B. R. A. Institute Rotary Cancer Hospital, All India Institute of Medical SciencesNew DelhiIndia
  2. 2.Department of Biomedical ScienceShaheed Rajguru College of Applied Sciences, University of DelhiNew DelhiIndia
  3. 3.Department of BiochemistryAll India Institute of Medical SciencesNew DelhiIndia
  4. 4.Department of BiostatisticsAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations